Introduction {#section1-2151458517743153}
============

Osteoporosis and associated fragility fractures are an age-related phenomenon. As the population continues to live longer, care must be taken to preserve bone health to ensure the quality of the additional years. By 2020, half of all people older than 50 will have decreased bone health.^[@bibr1-2151458517743153]^

Osteoporotic-related fractures present a substantial burden in morbidity, mortality, cost, and quality of life. Hip fractures carry up to a 36% mortality rate, a 2.5 times increased risk for a second fracture, and decreased mobility in 40% of patients.^[@bibr2-2151458517743153],[@bibr3-2151458517743153]^ Patients with hip fractures are 4 times more likely to die within the first 3 months after injury and a 1 in 5 chance of placement in a nursing home within the first year.^[@bibr1-2151458517743153]^ Fragility fractures occur every 3 seconds and affects 1 in 2 women and 1 in 4 men.^[@bibr4-2151458517743153]^ Direct care costs during the first post-fracture year are estimated to be US\$37000. per patient for hip fractures, US\$11300 for other nonvertebral fractures, and US\$8380 for vertebral fractures.^[@bibr5-2151458517743153]-[@bibr6-2151458517743153]^ A projected 25.3 billion US health-care dollars will be spent on fragility fractures by the year 2025.^[@bibr2-2151458517743153]^

Guidelines have been published for proper screening, diagnosis, and treatment of osteoporosis. However, a major gap in care exists because of a lack of awareness among patients and health-care providers.^[@bibr7-2151458517743153][@bibr8-2151458517743153][@bibr9-2151458517743153][@bibr10-2151458517743153][@bibr11-2151458517743153]-[@bibr12-2151458517743153]^ The Fracture Risk Assessment (FRAX) tool was developed by the World Health Organization (WHO) as an algorithm to assess individual fracture risk and it has been shown to be an integral part of initial screening for osteoporosis and fracture risk.^[@bibr2-2151458517743153],[@bibr13-2151458517743153]^ Multiple approaches ranging from treatment algorithms to a fracture liaison service (FLS) have been implemented to care for patients with fragility fracture. However, significant evidence-based knowledge gaps still persist for both patients as and health professionals.^[@bibr14-2151458517743153][@bibr15-2151458517743153][@bibr16-2151458517743153][@bibr17-2151458517743153]-[@bibr18-2151458517743153]^

The purpose of this quality improvement project was to address the clinical and administrative aspects of the addition of a screening tool that identifies patients who are at risk of osteoporosis and to aid in the prevention of sentinel fracture events by decreasing the risk of secondary fractures in patients 50 years and older. The goals of screening patients for fracture risk are to improve patient knowledge and quality of life and decrease associated mortality, morbidity, and cost of these fractures to health-care systems.

Patients and Methods {#section2-2151458517743153}
====================

Study Design and Population {#section3-2151458517743153}
---------------------------

The quality improvement initiative evaluated adults who presented to an orthopedic trauma clinic for routine follow-up care at a rural academic, level 1 trauma center from January 2016 to April 2016 using an osteoporosis screening questionnaire. Eligible patients were at least 50 years old and able to speak English. Exclusion criteria included all patients less than 50 years old and unable to speak English. A subset of 20 randomly selected patients participated in a pretest/posttest osteoporosis knowledge exercise to evaluate the effectiveness of patient teaching.

A waiver of consent was granted by our institutional review board. Eligible patients received a 15-question osteoporosis screening questionnaire upon check in for the scheduled follow-up clinic visit. The screening questionnaire provided to eligible patients was developed from the FRAX tool and included patient demographics (age, sex, height, and weight), as well as questions regarding personal and family history ([Figure 1](#fig1-2151458517743153){ref-type="fig"}). After completion of the questionnaire, an assessment of each patient's risk factors was completed and an FRAX score was calculated. The UK version of the FRAX tool was used to calculate the 10-year risk for a hip or other major osteoporotic fracture. The UK version of the tool has been accepted by the International Osteoporosis Foundation for use in all patient populations due to the treatment recommendations it generates.^[@bibr19-2151458517743153]^ The patients were plotted on a graph by age and FRAX score. This graph is stratified and assigns the patient to 1 of 3 risk stratums with accompanying intervention thresholds based on their age and FRAX score. It has been our experience that this patient pictorial is easy to incorporate in a clinical setting and furthermore, allowed for quick assessments and referral for additional workup of at-risk patients.

![Fracture risk assessment questionnaire.](10.1177_2151458517743153-fig1){#fig1-2151458517743153}

Risk stratum 1 included patients at low risk. Patients identified to be at low risk for fragility fractures received lifestyle intervention including bone health education regarding adequate calcium and vitamin D intake, weight-bearing exercise regimen, fall prevention, limiting alcohol intake, smoking cessation, and need for rescreening in 5 years. Risk stratum 2 included patients at intermediate risk. Patients in the intermediate risk stratum were recommended to undergo further evaluation of bone mineral density (BMD) by way of a dual-energy X-ray absorptiometry (DXA). After a DXA scan was completed, the FRAX score was recalculated to determine whether patients are above or below the intervention threshold. Risk stratum 3 included patients identified as high risk, based on a FRAX score, qualified for pharmacologic treatment of osteoporosis, with or without additional measurement of BMD by the way of DXA.^[@bibr13-2151458517743153],[@bibr16-2151458517743153]^ Patients in all 3 risk stratums received education with their standard treatment.

Intervention {#section4-2151458517743153}
------------

The project coordinator met with a subset of 20 randomly selected patients without a prior history of osteoporosis. A 5-question pretest was administered to assess the patient's knowledge regarding osteoporosis. The coordinator also used the allotted time to educate the patient on osteoporosis pathology and modifiable/nonmodifiable risk factors via a handout and discussion. Upon the completion of patient education, a posttest was administered. The pretest/posttest can be found in [Figure 2](#fig2-2151458517743153){ref-type="fig"}.

![Pretest/posttest questions.](10.1177_2151458517743153-fig2){#fig2-2151458517743153}

Demographics {#section5-2151458517743153}
------------

Patient demographics were extracted from the screening questionnaire and incorporated into the FRAX risk assessment. Data included patient age, sex, and race.

Statistical Analysis {#section6-2151458517743153}
--------------------

Demographic variables were analyzed using descriptive statistics: means were calculated for age. Gender counts were completed. Total counts and percentages of the total sample were completed for each risk stratum. Percentage change was calculated between the pretest and posttest score using a 1-tailed paired *t* test to determine the significance level of knowledge gained.

Source of Funding {#section7-2151458517743153}
-----------------

No external funding source was used in the execution of this study.

Results {#section8-2151458517743153}
=======

During the 3-month project time frame, 804 total patient visits for routine, orthopedic trauma follow-up occurred. Four hundred and five patient visits met the inclusion criteria. Repeat visits accounted for 108 of the total visits, resulting in 297 eligible patients of whom 291 were screened. A breakdown of demographic data can be found in [Table 1](#table1-2151458517743153){ref-type="table"}.

###### 

Patient Demographics.

![](10.1177_2151458517743153-table1)

  ------------------- -------
  Gender              
   Male               41.2%
   Female             58.7%
  Age                 
   Mean               65.8
   Range              50-98
  Race                
   Caucasian          275
   African American   12
   Hispanic           3
   Asian              1
  ------------------- -------

The patients meeting eligibility for screening during the study time frame (97.7%) accounted for 42% of the clinic population. Of the 291 patients screened, 165 (56.7%) met criteria for additional follow-up via a DXA scan to evaluate BMD, or they were recommended for pharmacological treatment of osteoporosis (stratums 2 and 3). This composed 97 (33.3%) patients within the intermediate-risk range (stratum 2) and 68 (23.4%) patients within the high-risk range (stratum 3). These 165 patients represent 23.6% of the total practice population. The remaining 126 (43.3%) patients fell in to the low-risk stratum and only lifestyle advice was given. An unexpected finding of the study was that only 9.8% (28) of patients screened were receiving osteoporosis treatment at the time of evaluation.

Twenty patients were randomly selected to participate in the pretest/posttest to evaluate their knowledge regarding osteoporosis. All patients were Caucasian---9 were males (ages 53-78 with a mean age of 61.6) and 11 were females (ages 51-78 with a mean age of 59.5). The patients had a 33% gain in knowledge which was statistically significant (at *P* =.0004). The largest knowledge deficit/gain was found in 35% of the patients and involved risk factors and lifestyle management to prevent osteoporosis.

Discussion {#section9-2151458517743153}
==========

The need to screen for osteoporosis and fragility fracture risk is clearly supported by this project. More than half (56.7%) of the patients seen during routine visits met the recommendations for screening by the WHO and the National Osteoporosis Foundation (NOF). The American Academy of Orthopedic Surgeons (AAOS) has given a moderate recommendation in its clinical practice guidelines for evaluation and treatment of osteoporosis in patients with hip fractures. However, based on the substantial portion of the population identified in our study as "at risk" through a simple screening questionnaire, we feel these recommendations should be expanded to include all patients over the age of 50. Without screening this vulnerable population, those at risk do not receive adequate diagnosis or treatment and are at increased risk of debilitating, costly, and often fatal fractures. As seen in this study, only 9.8% of patient screened were receiving treatment at the time of evaluation, but an additional 13.8% fell into risk stratum 3, suggesting treatment is necessary. Furthermore, 33.3% of patients fell into risk stratum 2 and were noted to have enough risk factors to warrant further evaluation with BMD testing. This indicates that treatment and/or further workup would not have been provided to 46.7% of those in need in our patient population without an FLS.

The project outcomes support previous work---in the use of an advanced practice provider (nurse practitioner or physician assistant) dedicated to the management of an FLS as vital to successful screening and treatment of osteoporosis helping close the gap between fragility fractures and osteoporosis management.^[@bibr18-2151458517743153]^ The advanced practice provider should incorporate the FRAX tool when screening the at-risk population. Once the initial screen is completed, the advanced practice provider can provide patient education, obtain additional screening measures, manage referrals for additional care, and prescribe pharmacologic management.

Findings are also supportive of previous studies that highlight the importance of an orthopedic surgeon serving as the physician champion on the FLS.^[@bibr7-2151458517743153]^ The orthopedic surgeon has established a relationship with the patient by virtue of treating his or her fracture and is the person the patient will continue to see for fracture care.

Constraints of the FRAX tool have been identified previously. Limitations include the inability to take into consideration dose-related questions (use of glucocorticoids, alcohol, tobacco, and number of previous fractures) as well as an individual's fall risk.^[@bibr20-2151458517743153]^ Several studies have proposed inequalities in the strength of fracture risk predictions in various subsets of populations when using the FRAX, namely, that the risk is underestimated in some portions of the world's population.^[@bibr21-2151458517743153][@bibr22-2151458517743153][@bibr23-2151458517743153][@bibr24-2151458517743153][@bibr25-2151458517743153]-[@bibr26-2151458517743153]^ However, the FRAX tool has been accepted by the WHO, NOF, and AAOS as the best screening tool and is readily available from <https://www.shef.ac.uk/FRAX/> without charge. Therefore, the FRAX tool should be used as the beginning point of screening combined with clinical judgment when rendering a plan of care for individualized patients.

Conclusion {#section10-2151458517743153}
==========

Osteoporosis and associated fragility fractures will continue to affect the growing elderly population unless providers incorporate screening guidelines into daily practice. Our study shows that the implementation of an osteoporosis screening tool to identify, risk stratify, and treat patients with osteoporosis and related fragility fractures can be successfully integrated into a busy clinical practice. However, the authors acknowledge the pilot project was undertaken with the addition of a project coordinator to the clinic staff. Successful implementation of an FLS may be dependent on the introduction of a qualified provider to manage the service.
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